Harvest Fund Management Co. Ltd Buys 860 Shares of Glaukos Co. (NYSE:GKOS)

Harvest Fund Management Co. Ltd grew its stake in Glaukos Co. (NYSE:GKOS) by 2,263.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 898 shares of the medical instruments supplier’s stock after purchasing an additional 860 shares during the quarter. Harvest Fund Management Co. Ltd’s holdings in Glaukos were worth $117,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Values First Advisors Inc. acquired a new position in Glaukos in the 3rd quarter valued at about $25,000. GAMMA Investing LLC grew its position in shares of Glaukos by 68.8% in the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after purchasing an additional 486 shares during the last quarter. Fifth Third Wealth Advisors LLC bought a new position in shares of Glaukos during the second quarter worth approximately $187,000. KBC Group NV lifted its holdings in Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after purchasing an additional 201 shares during the last quarter. Finally, Brighton Jones LLC bought a new stake in Glaukos in the 2nd quarter valued at $208,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Price Performance

Glaukos stock opened at $142.68 on Thursday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos Co. has a 52 week low of $59.58 and a 52 week high of $146.86. The stock has a market capitalization of $7.87 billion, a P/E ratio of -47.25 and a beta of 1.02. The stock has a fifty day moving average of $133.15 and a 200-day moving average of $124.27.

Glaukos (NYSE:GKOS) last issued its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. During the same quarter in the previous year, the firm earned ($0.50) earnings per share. The business’s quarterly revenue was up 23.9% on a year-over-year basis. On average, sell-side analysts expect that Glaukos Co. will post -1.96 earnings per share for the current fiscal year.

Insider Activity at Glaukos

In other news, Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the transaction, the director now owns 32,336 shares of the company’s stock, valued at $4,225,345.12. This represents a 8.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Joseph E. Gilliam sold 2,275 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the transaction, the chief operating officer now owns 102,169 shares of the company’s stock, valued at approximately $14,198,425.93. This trade represents a 2.18 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

GKOS has been the topic of several recent research reports. JPMorgan Chase & Co. increased their price objective on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. StockNews.com upgraded shares of Glaukos from a “sell” rating to a “hold” rating in a research note on Monday, October 21st. Wells Fargo & Company increased their target price on shares of Glaukos from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. BTIG Research lifted their price target on shares of Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Truist Financial increased their price target on Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $135.45.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.